InnoCare announces the appointment of a new CCO , Mr. Xiaodong Jin

On June 28, 2020, InnoCare (Stock Code:09969-HK), a leading innovator for global biopharmaceutical drugs, is proud to announce the appointment of Mr. Xiaodong Jin as Chief Commercial Officer (CCO). Reporting directly to the Co-funder, Chairman and CEO, Dr. Jasmine Cui, Mr. Xiaodong Jin  will lead sales, marketing, market access and DCM team to execute the company’s commercial strategy.

Mr. Xiaodong Jin has more than 24 years’ solid experience in production commercialization in global pharmaceutical industry. Before joining InnoCare, Mr. Jin served as General Manager of Cardiovascular Business Unit at Sanofi (China) Investment Co., Ltd. Shanghai Branch. He also served as General Manager of Abbott Diabetes Care and Head of Greater China in Abbott Laboratories Trading (Shanghai) Co,. Ltd. Prior to that, Mr. Jin had served Beijing Novartis Pharmaceutical Company Ltd. for more than 13 years, as Sales Manager, Regional Sales Director, Marketing Director and Head of Chengdu Branch successively. Mr. Jin holds an executive master of business administration degree (EMBA) from Peking University.

Dr. Jasmine Cui, Co-funder, Chairman and CEO of InnoCare, said, "We are very pleased to have Xiaodong Jin on board. During working in  MNCs, Xiaodong successfully led team obtained remarkable commercial achievements. His extensive and highly successful commercial experience in the pharmaceutical field will accelerate the progress of InnoCare into new commercial areas and greater commercial breakthroughs. "

"I am honored to join InnoCare at this moment, to witness and participate in the rise of an outstanding innovative drug company." Mr. Xiaodong Jin said, " InnoCare 's efficient development in recent years have attracted considerable attention. I look forward to working with these talents closely to contribute more to the society and benefit the patient."